Viatris completes biosimilars transaction with biocon biologics

Receives a $2 billion cash payment and $1 billion of convertible preferred equity representing a stake of at least 12.9% (on a fully diluted basis) in biocon biologics marks the first in a series of expected initiatives to reshape and rebase viatris, aimed at setting it up for long-term growth pittsburgh , nov. 29, 2022 /prnewswire/ -- viatris inc. (nasdaq: vtrs) today announced that it has closed its transaction with biocon biologics limited ("biocon biologics"), creating what viatris expects to be a unique fully vertically integrated global biosimilars leader. viatris and biocon biologics have entered a transition services agreement (tsa) pursuant to which viatris will provide commercialization and certain other transition services for an expected two-year period intended to ensure business continuity for patients, customers and colleagues.
VTRS Ratings Summary
VTRS Quant Ranking